Glioblastoma Cancer Clinical Trial

Glioblastoma (GBM) is an aggressive and frequently lethal brain malignancy, which is usually resistant to conventional therapies and immunotherapies. GBM has an incidence of two to three per 100,000 adults per year, and accounts for 52 percent of all primary brain tumors.

We are currently developing a protocol to treat recurrent glioblastoma using Aldoxorubicin and our Anktiva.

Dr. Patrick Soon-Shiong
Executive Chairman, ImmunityBio
This unique approach to orchestrating the innate and adaptive immune systems to induce immunogenic cell death may be an important new approach for pancreatic cancer patients—these being among the most challenging to treat with poor prognosis.

Recent Research

Recent News

How Can ImmunityBio Help You?

Solutions for Patients

Many therapies for treating cancer and infectious diseases severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Opportunities for Trial Investigators

Natural killer cell-based immunotherapies are key to future cancer treatments. Our investigational NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.

Solutions for Research Scientists

Our NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.